Omicsveu’s Post

𝐖𝐡𝐲 𝐂𝐆𝐏? Comprehensive genomic profiling (CGP) offers simultaneous assessment of multiple biomarkers in a single assay, and has numerous benefits over single-gene assays. Neo Comprehensive™ – Solid Tumor is a broad, next-generation sequencing panel for pan-solid tumor indications. The test profile includes 517 genes by DNA for single nucleotide variants (SNVs) and short insertions/deletions (InDels). https://lnkd.in/g9ZW3Kx9

The success of your research depends on the methodic and accurate selection of the most relevant tumor models. Lumin Analytics eliminates the guesswork and gives you access to the most comprehensive model characterization data in the industry. Explore Champions’ patient-derived preclinical model characteristics: ☑️Clinical annotations ☑️Proprietary genomic and proteomic profiles ☑️Proprietary in vivo pharmacological profiles Make data-driven decisions with confidence and accelerate your oncology research programs. Explore here: https://hubs.li/Q02LGrg80 #Lumin #modelselection #omics #genomics #proteomics #oncologyresearch #cancerresearch #clinicalannotations #oncology

This week, our CEO, Marc Stapley, shares insights on how Veracyte is helping to address equity gaps in healthcare and what sets our company apart. Additionally, two new studies suggest that #Decipher Prostate may help clinicians more accurately assess risk for prostate cancer patients eligible for active surveillance. Thank you for following our news: 1️⃣ Veracyte’s RNA Genetic Test Predicts Aggressive Prostate Cancer in Black Men – Jonathan D. Grinstein, PhD, Inside Precision Medicine 2️⃣ The Care Continuum: Veracyte’s CEO on its Diagnostic Strategy – Haydn Brain, OPTO 3️⃣ The Future is Bright for Veracyte and Molecular Diagnostics – OPTO 4️⃣ Genomic Testing Helps Personalize Care for Prostate Cancer Patients – Mark L. Fuerst, Oncology Times 🔗 Read the full articles and more on Veracyte in the news: https://lnkd.in/ga-zvGrd #prostatecancer #biotechindustry #biotechnology #biotech #MRDtechnology #genomictesting #cancertests #decipherprostatetest #moleculardiagnostics #VCYT

We are excited to present a collection of application notes featuring data on KingFisher's automated magnetic bead sample extraction technology. This cutting-edge method isolates high-quality DNA, RNA, proteins, and cells, driving advancements in cancer research, microbiome studies, viral research, and beyond. Key Highlights: 🧬 Reliable results for cancer biomarker discovery 🌱 Precision in microbiome studies 🦠 Enhanced viral pathogen detection 📊 Explore the application notes and accompanying date here: https://lnkd.in/gK8jsG3i

Looking to enrich your cancer research with the latest advancements in urine liquid biopsy and neoantigen discovery for cancer immunotherapy? 📢 Join our Spotlight Theater presentation: April 8, 2024, from 10 a.m. to 11 a.m. PDT, Room D. What are the sessions about? • Session 1 – Evaluation of preanalytical workflows for molecular profiling of urinary cell-free DNA in malignant disease (Presenter: Ellen Heitzer, PhD, Medicinal University Graz, Austria) • Session 2 – Uncovering immunogenic neo-peptides from actionable RNA fusions for cancer immunotherapy (Presenter: Sakuni Rankothgedera, University of Houston)

Choosing the right models for our new TumorGraft3D 100 Model Screen is crucial for a successful study. Explore Champions’ Lumin platform to access extensive multi-omic datasets that can assist in selecting the best models. Leverage the Target and Biomarker Discovery tool to pinpoint models that demonstrate sensitivity or resistance to a specific standard of care drug, and identify genetic markers of response to the treatment. By using these markers, you can identify other models with similar responses to the drug. Powered by Lumin, access now: https://hubs.li/Q02p-DCP0 Enroll in our new TumorGraft3D 100 Model Screen: https://hubs.li/Q02p-x0f0 #PoweredByLumin #Omics #Multiomics #Biomarker #TumorGraft3D #Lumin #Genes #OncologyResearch #CancerResearch #Oncology #Cancer #Bioinformatics #organoid

#TechnologyTuesday 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝘀𝗲𝘁 𝗳𝗼𝗿 𝗲𝗮𝗿𝗹𝘆 𝗮𝗻𝗱 𝗻𝗼𝗻-𝗶𝗻𝘃𝗮𝘀𝗶𝘃𝗲 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 𝗮𝗻𝗱 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁𝗶𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗿𝗲𝗻𝗮𝗹 𝗰𝗲𝗹𝗹 𝗰𝗮𝗿𝗰𝗶𝗻𝗼𝗺𝗮𝘀 🔺 Clear cell renal cell carcinoma (#ccRCC) - the most common and one of the deadliest subtypes of #kidney #cancer - can be asymptomatic for a long time, often leading to late-stage #diagnosis and poor outcomes. The #tumour subtype can be assessed histologically, but validated #liquid #biopsy #biomarkers for early-stage disease #screening and detection are currently lacking.   💡 Scientists from Institute of Molecular Biotechnology have identified a #novel #biomarker #set that enables early and non-invasive diagnosis and differentiation of renal cell carcinomas from urinary samples. By developing a pre-selectable peptide signature and using parallel reaction monitoring mass spectrometry (PRM-MS), they established a combined #UrineScore that accurately diagnoses #ccRCC and performs well in discriminating non-ccRCC from ccRCC malignancies.   👨🔬 #Inventors: Gustav Jonsson, Tiago Fontes Oliveira & Josef Penninger 🔎 Learn more: https://lnkd.in/dpgWCpyh #RenalCellCarcinoma #MassSpectrometryBasedDiagnostics #LiquidBiopsy

I'm happy to share our recent Genetic Engineering & Biotechnology News webinar in which I and Dr. Arutha Kulasinghe are discussing AI's role in discovering biomarkers for immunotherapy through spatial analysis of multiplex imaging (mIF) data. In this talk we share a novel method for cell subtyping from mIF data, and the identification of a lung cancer metabolic state which is associated with immunotherapy resistance using this method. Visit the link to watch now! https://lnkd.in/diAd_xyg #immunotherapy #spatialbiomarkers #CDx #mIF #digitalpathology #biomarkers #precisionmedicine

🧬 TruSight™ Oncology 500 : Now More Accessible with NextSeq™ 2000! Gain a deeper understanding of the complex nature of cancer biology by analyzing both DNA and RNA-based tumor profiles with an extensive gene panel. ⭐️Now, with the NextSeq 1000/2000 platform, TSO500™ HT applications become even more accessible and easier to implement! ⭐️Utilize the speed, flexibility, and high data quality provided by XLEAP-SBS chemistry which allows you to obtain faster results in your research, processing up to 36 samples per batch. ⭐️Do you have more samples or not enough to fill up a NextSeq 2000? We got you covered! You can also run TSO 500 HT on NextSeq 550 and NovaSeq™ 6000. Empower your research with the tools you need for comprehensive genomic profiling. 💡🔬 #NextSeq2000 #NextSeq550 #NovaSeq6000 #TSO500 #CGP #GenomicAnalysis #Oncology #Illumina #GenomicProfiling

Analysis of CTCs and ctDNA from liquid biopsy (LB) samples can provide molecular insights into cancer progression, survival and treatment. Discover a new workflow for the Genesis System and Celselect Slides™ for co-isolation and analysis of CTCs and ctDNA from LB samples. Get the App Note: https://ow.ly/Glm650Qxnf4 Learn more about the Genesis System and Celselect Slides™ here: https://ow.ly/hjlP50Qxnf3 #CelselectSlides #CTC #LiquidBiopsy